Odyssey Therapeutics, Inc. (ODTX)
NASDAQ: ODTX · Real-Time Price · USD
23.34
+0.28 (1.21%)
At close: Sep 22, 2026, 4:00 PM EDT
23.36
+0.02 (0.09%)
After-hours: Sep 22, 2026, 4:54 PM EDT
Odyssey Therapeutics Revenue
Odyssey Therapeutics had revenue of $99.00K in the twelve months ending June 30, 2026, down -96.70% year-over-year. In the year 2025, Odyssey Therapeutics had annual revenue of $2.98M, down -33.45%.
Revenue (ttm)
$99.00K
Revenue Growth
-96.70%
P/S Ratio
11,297.14
Revenue / Employee
$990
Employees
100
Market Cap
1.12B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.98M | -1.50M | -33.45% |
| Dec 31, 2024 | 4.47M | 3.44M | 331.24% |
| Dec 31, 2023 | 1.04M | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
ODTX News
- 6 days ago - Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum - GlobeNewsWire
- 8 days ago - Odyssey Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 13 days ago - H.C. Wainwright has increased confidence in Odyssey after Beeline data - TheFly
- 26 days ago - Odyssey Therapeutics initiated with a Buy at H.C. Wainwright - TheFly
- 27 days ago - Odyssey Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Evotec enters R&D collaboration with Odyssey Therapeutics - TheFly
- 6 weeks ago - Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - PRNewsWire
- 7 weeks ago - Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire